banner
 
bar

program

slides
bar
 
 

The Science and Application of Antithrombotic Interventions for
High Risk ACS

WebCAST

pre-program survey
We Invite You to Take a Moment and Complete This
Pre-Program Knowledge and Clinical Performance Survey.
Thank You

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period December 1, 2011 through December 1, 2013, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 6 segments totaling 2 hours and 12 minutes to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate

Estimated Time to Complete Educational Activity:

2.5 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in antithrombotic interventions for patients with high risk acute coronary syndrome.

Release Date:

December 1, 2011

Expiration Date:

December 1, 2013

Intended Audience:

This program is intended for all cardiovascular-focused clinicians, investigators, program directors, and healthcare providers caring for patients with cardiovascular disease, ACS, and related conditions

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

logoThis CME activity is supported by an
educational grant from sanofi-aventis

Physician Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Program Faculty and Disclosures:

DEEPAK L. BHATT, MD, MPH, FACC, FAHA, FSCAI
(Program Chairperson)
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular Program,
Brigham and Women's Hospital & VA Boston Healthcare System
Associate Professor of Medicine
Harvard Medical School
Senior Investigator, TIMI Study Group
Boston, MA

Grant/Research Support: Astra Zeneca, Bristol Myers Squibb, Eisai,
Sanofi-Aventis, The Medicines Company



SUNIL V. RAO, MD, FACC, FSCAI
Director, Cardiac Catheterization Laboratories
Durham VA Medical Center
Associate Professor of Medicine
Duke University Medical Center
Chapel Hill, MC

Consultant: Terumo Medical, Zoll, Astra Zeneca, The Medicines Company
Speaker's Bureau: Abbott Vascular, Boehringer Ingelheim
Grant/Research Support: Cordis Corporation, Ikaria




DAVID P. FAXON, MD
Vice Chair of Medicine
Brigham and Women's Hospital
Senior Lecturer
Harvard Medical School
Boston, MA

Consultant: Boston Scientific
Grant/Research Support: Sanofi-Aventis
Shareholder: RIVA Medical




GREGG W. STONE MD
Director of Cardiovascular Research & Education
The Cardiovascular Research Foundation
Professor of Medicine
Columbia University Medical Center
New York, NY

Consultant: Boston Scientific, Abbott Vascular, The Medicines Company, Merck, Eli Lilly- Daiichi Sankyo, Astra Zeneca, BMS-Sanofi

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives:

Upon completion of this activity, attendees will:

  1. Be better educated about and more proficient at applying current ACC/AHA/ESC/SCAI guidelines as they relate to use of anticoagulation in patients undergoing invasive management of ACS
  2. Be more skilled at optimizing stent-based invasive treatment of ACS, based on proper risk stratification strategies
  3. Be better informed about and better understand emerging advances and trials investigating the safety and efficacy of anticoagulants affecting targeted factors in the clotting cascade, including factor Xa inhibition; and, better understand the possible implications that such agents may have on outcomes, bleeding, and other end points in ACS patients who are managed with an invasive strategy
  4. Become more skilled at identifying ACS patients who are amenable to an invasive strategy for treatment, and better able to interpret the clinical implications of studies outlining how to implement antithrombotic interventions for this subgroup, with a focus on thrombotic and bleeding end points
  5. Become better educated about the dosing, selection, and evidence-based guidelines for IC-based management—including anticoagulants and antiplatelet agents—of ACS patients who, based on risk stratification criteria or findings at angiography, require treatment with an invasive strategy

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer:

Copyright © 2011 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, or the program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

pre-program survey
We Invite You to Take a Moment and Complete This
Pre-Program Knowledge and Clinical Performance Survey.
Thank You
bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © 2011 Resources, LLC All rights reserved

 
6

 

Key Program Topics Include:

ACUITY
Acute MI
ADP–P2Y12 receptor antagonist
AMI
Anticoagulation
Antithrombotic
Apixaban
APPRAISE
ATLAS ACS
ATOLL
ATP
Betrixaban
Bivalirudin
Bleeding

BMS
Cangrelor
CHAMPION PHOENIX
Clopidogrel
coagulation
COGENT
Darexaban
DES
Direct Factor Xa Inhibitors
Direct Thrombin
Edoxaban
Embolic
Enoxaparin
Factor Xa Inhibition
Femoral arterial

FINESSE
Fluroscopy
GP IIb/IIIa Inhibition
GUSTO IIb
HORIZONS-AMI
Letaxaban
LMWH
NSTE ACS
Otamixaban
PARAGON
PCI
Periprocedural MI
PURSUIT
Radial
REPLACE-2

RIVAL
Rivaroxaban
RUBY 1
SEPIA ACS
SPIRIT IV
Stent
TAO
Thrombectomy
Thrombosis
TIMI 46
TLR
Transradial
TRITON-TIMI-38
HORIZONS-AMI
UFH
WARIS II